on TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. Engages in Virtual Investor Conference
On February 19, 2025, TuHURA Biosciences, Inc. (NASDAQ:HURA) took part in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. CEO Dr. James Bianco highlighted five key reasons for investors and industry experts to consider the company's potential this year.
TuHURA, a Phase 3 immune-oncology firm, is advancing technologies to tackle resistance to cancer immunotherapy. Their lead candidate, IFx-2.0, is set for a Phase 3 trial alongside Keytruda® for treating Merkel Cell Carcinoma.
Additionally, TuHURA focuses on innovative bi-specific ADCs and PDCs aimed at mitigating Myeloid Derived Suppressor Cells' effects and supporting immune response.
The conference presentation is available for viewing on the company’s website.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TuHURA Biosciences, Inc. news